Integration of HPV6 and Downregulation of AKR1C3 Expression Mark Malignant Transformation in a Patient with Juvenile-Onset Laryngeal Papillomatosis

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Huebbers, Christian Ulrich ^a   Preuss, Simon Florian ^b   Kolligs, Jutta ^a   Vent, Julia ^b   Stenner, Markus ^b   Wieland, Ulrike ^b   Silling, Steffi ^b   Drebber, Uta ^b   Speel, Ernst Jan M ^c   Klussmann, Jens Peter ^d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOKETOREDUCTASE 1C3; CARBOPLATIN; CELL DNA; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FLUOROURACIL; OXIDOREDUCTASE; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA;

ADJUVANT THERAPY; ADULT; AKR1C3 GENE; ARTICLE; CANCER RADIOTHERAPY; CARCINOGENESIS; CASE REPORT; CELL NUCLEUS; CHROMOSOME 10P; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOCHEMISTRY; DISEASE ASSOCIATION; DOWN REGULATION; EPISOME; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; LARYNGECTOMY; LARYNX CARCINOMA; LARYNX PAPILLOMATOSIS; LARYNX SURGERY; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; ONCOGENE; ONSET AGE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; TISSUE SECTION; VIRUS DNA CELL DNA INTERACTION; VIRUS IDENTIFICATION; WESTERN BLOTTING;

3-HYDROXYSTEROID DEHYDROGENASES; ADULT; AGE OF ONSET; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DOWN-REGULATION; FATAL OUTCOME; FEMALE; HUMAN PAPILLOMAVIRUS 6; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; LARYNGEAL NEOPLASMS; PAPILLOMA; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874261118     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057207     Document Type: Article

References (51)

1. Gissmann L, Diehl V, Schultz-Coulon HJ, Hausen zur H, (1982) Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma. J Virol 44: 393-400.
2. Major T, Szarka K, Sziklai I, Gergely L, Czeglédy J, (2005) The characteristics of human papillomavirus DNA in head and neck cancers and papillomas. J Clin Pathol 58: 51-55 doi:10.1136/jcp.2004.016634.
3. Strong MS, Vaughan CW, Cooperband SR, Healy GB, Clemente MA, (1976) Recurrent respiratory papillomatosis: management with the CO2 laser. Ann Otol Rhinol Laryngol 85: 508-516.
4. Ullmann (1923) On the actiology of laryngeal papilloma. Acta Otolaryngology pp. 317-325.
5. Abramson AL, Steinberg BM, Winkler B, (1987) Laryngeal papillomatosis: clinical, histopathologic and molecular studies. Laryngoscope 97: 678-685.
6. Cook JR, Hill DA, Humphrey PA, Pfeifer JD, El-Mofty SK, (2000) Squamous cell carcinoma arising in recurrent respiratory papillomatosis with pulmonary involvement: emerging common pattern of clinical features and human papillomavirus serotype association. Mod Pathol 13: 914-918 doi:10.1038/modpathol.3880164.
7. Gerein V, Rastorguev E, Gerein J, Draf W, Schirren J, (2005) Incidence, age at onset, and potential reasons of malignant transformation in recurrent respiratory papillomatosis patients: 20 years experience. Otolaryngology- Head and Neck Surgery 132: 392-394 doi:10.1016/j.otohns.2004.09.035.
8. Lin HW, Richmon JD, Emerick KS, de Venecia RK, Zeitels SM, et al. (2010) Malignant transformation of a highly aggressive human papillomavirus type 11-associated recurrent respiratory papillomatosis. Am J Otolaryngol 31: 291-296 doi:10.1016/j.amjoto.2009.02.019.
9. Reidy PM, Dedo HH, Rabah R, Field JB, Mathog RH, et al. (2004) Integration of Human Papillomavirus Type 11 in Recurrent Respiratory Papilloma-Associated Cancer. Laryngoscope 114: 1906-1909 doi:10.1097/01.mlg.0000147918.81733.49.
10. Capper JW, Bailey CM, Michaels L, (1983) Squamous papillomas of the larynx in adults. A review of 63 cases. Clin Otolaryngol Allied Sci 8: 109-119.
11. Preuss SF, Klussmann JP, Jungehulsing M, Eckel HE, Guntinas-Lichius O, et al. (2007) Long-term results of surgical treatment for recurrent respiratory papillomatosis. Acta Otolaryngol 127: 1196-1201 doi:10.1080/00016480701200350.
12. Campisi G, Panzarella V, Giuliani M, Lajolo C, Di Fede O, et al. (2007) Human papillomavirus: its identity and controversial role in oral oncogenesis, premalignant and malignant lesions (review). Int J Oncol 30: 813-823.
13. Goon PKC, Stanley MA, Ebmeyer J, Steinsträsser L, Upile T, et al. (2009) HPV & head and neck cancer: a descriptive update. Head Neck Oncol 1: 36 doi:10.1186/1758-3284-1-36.
14. Kashima H, Wu TC, Mounts P, Heffner D, Cachay A, et al. (1988) Carcinoma ex-papilloma: histologic and virologic studies in whole-organ sections of the larynx. Laryngoscope 98: 619-624 doi:10.1288/00005537-198806000-00008.
15. Ragin CCR, Modugno F, Gollin SM, (2007) The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. Journal of Dental Research 86: 104-114.
16. Kim L, King T, Agulnik M, (2010) Head and neck cancer: changing epidemiology and public health implications. Oncology (Williston Park, NY) 24: 915-924, 915-919, 924.
17. Lace MJ, Anson JR, Klussmann JP, Wang DH, Smith EM, et al. (2011) Human papillomavirus type 16 (HPV-16) genomes integrated in head and neck cancers and in HPV-16-immortalized human keratinocyte clones express chimeric virus-cell mRNAs similar to those found in cervical cancers. J Virol 85: 1645-1654 doi:10.1128/JVI.02093-10.
18. Kraus I, Driesch C, Vinokurova S, Hovig E, Schneider A, et al. (2008) The Majority of Viral-Cellular Fusion Transcripts in Cervical Carcinomas Cotranscribe Cellular Sequences of Known or Predicted Genes. Cancer Res 68: 2514-2522 doi:10.1158/0008-5472.CAN-07-2776.
19. Wieland U, Ritzkowsky A, Stoltidis M, Weissenborn S, Stark S, et al. (2000) Communication: papillomavirus DNA in basal cell carcinomas of immunocompetent patients: an accidental association? J Invest Dermatol 115: 124-128 doi:10.1046/j.1523-1747.2000.00015.x.
20. Schmitt M, Bravo IG, Snijders PJF, Gissmann L, Pawlita M, et al. (2006) Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 44: 504-512 doi:10.1128/JCM.44.2.504-512.2006.
21. Schmitt M, Dondog B, Waterboer T, Pawlita M, (2008) Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol 46: 1050-1059 doi:10.1128/JCM.02227-07.
22. Klussmann JP, Weissenborn SJ, Wieland U, Dries V, Kolligs J, et al. (2001) Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 92: 2875-2884.
23. Wittekindt C, Gültekin E, Weissenborn SJ, Dienes HP, Pfister HJ, et al. (2005) Expression of p16 protein is associated with human papillomavirus status in tonsillar carcinomas and has implications on survival. Adv Otorhinolaryngol 62: 72-80 doi:10.1159/000082474.
24. Hafkamp HC, Mooren JJ, Claessen SM, Klingenberg B, Voogd AC, et al. (2009) P21Cip1/WAF1 expression is strongly associated with HPV-positive tonsillar carcinoma and a favorable prognosis. Modern Pathology 22: 686-698 doi:10.1038/modpathol.2009.23.
25. Hafkamp HC, Speel EJ, Haesevoets A, Bot FJ, Dinjens WN, et al. (2003) A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer 107: 394-400 doi:10.1002/(ISSN)1097-0215.
26. Hafkamp HC, Manni JJ, Haesevoets A, Voogd AC, Schepers M, et al. (2008) Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer 122: 2656-2664 doi:10.1002/ijc.23458.
27. Hopman AHN, Smedts F, Dignef W, Ummelen M, Sonke G, et al. (2004) Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. J Pathol 202: 23-33 doi:10.1002/path.1490.
28. Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, et al. (1999) Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 59: 6132-6136.
29. Frohman MA, Dush MK, Martin GR, (1988) Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer. Proc Natl Acad Sci USA 85: 8998-9002.
30. IACR protocol Detection of TP53 mutations by direct sequencing (n.d.) IACR protocol Detection of TP53 mutations by direct sequencing. 2010 ed. Available: http://www-p53.iarc.fr/Download/TP53_DirectSequencing_IARC.pdf. Accessed 31 October 2012.
31. Hartley BE, (1994) Uvulectomy to prevent throat infections. J Laryngol Otol 108: 921.
32. Klozar J, Taudy M, Betka J, Kana R, (1997) Laryngeal papilloma-precancerous condition? Acta Otolaryngol Suppl 527: 100-102.
33. Derkay CS, (1995) Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg 121: 1386-1391.
34. Donne AJ, Hampson L, Homer JJ, Hampson IN, (2010) The role of HPV type in Recurrent Respiratory Papillomatosis. Int J Pediatr Otorhinolaryngol 74: 7-14 doi:10.1016/j.ijporl.2009.09.004.
35. Wentzensen N, Ridder R, Klaes R, Vinokurova S, Schaefer U, et al. (2002) Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions. Oncogene 21: 419-426 doi:10.1038/sj.onc.1205104.
36. Begum S, Cao D, Gillison M, Zahurak M, Westra WH, (2005) Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 11: 5694-5699 doi:10.1158/1078-0432.CCR-05-0587.
37. Koskinen WJ, Chen RW, Leivo I, Mäkitie A, Bäck L, et al. (2003) Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. Int J Cancer 107: 401-406 doi:10.1002/ijc.11381.
38. Hudelist G, Manavi M, Pischinger KID, Watkins-Riedel T, Singer CF, et al. (2004) Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol 92: 873-880 doi:10.1016/j.ygyno.2003.11.035.
39. Kahn T, Turazza E, Ojeda R, Bercovich A, Stremlau A, et al. (1994) Integration of human papillomavirus type 6a DNA in a tonsillar carcinoma: chromosomal localization and nucleotide sequence of the genomic target region. Cancer Res 54: 1305-1312.
40. Lockwood WW, Coe BP, Williams AC, Macaulay C, Lam WL, (2007) Whole genome tiling path array CGH analysis of segmental copy number alterations in cervical cancer cell lines. Int J Cancer 120: 436-443 doi:10.1002/ijc.22335.
41. Thorland EC, Myers SL, Gostout BS, Smith DI, (2003) Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene 22: 1225-1237 doi:10.1038/sj.onc.1206170.
42. Wagatsuma M, Hashimoto K, Matsukura T, (1990) Analysis of integrated human papillomavirus type 16 DNA in cervical cancers: amplification of viral sequences together with cellular flanking sequences. J Virol 64: 813-821.
43. Entrez Genome view (n.d.) Entrez Genome view. Accessed 31 October 2012.
44. Penning TM, Byrns MC, (2009) Steroid hormone transforming aldo-keto reductases and cancer. Ann N Y Acad Sci 1155: 33-42 doi:10.1111/j.1749-6632.2009.03700.x.
45. Wanichwatanadecha P, Sirisrimangkorn S, Kaewprag J, Ponglikitmongkol M, (2012) Transactivation activity of human papillomavirus type 16 E6*I on aldo-keto reductase genes enhances chemoresistance in cervical cancer cells. Journal of General Virology 93: 1081-1092 doi:10.1099/vir.0.038265-0.
46. Ji Q, Chang L, Stanczyk FZ, Ookhtens M, Sherrod A, et al. (2007) Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling. Cancer Res 67: 1361-1369 doi:10.1158/0008-5472.CAN-06-1593.
47. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T, (1998) Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. The American Journal of Pathology 153: 1741-1748.
48. Mooren J, Gültekin E, Straetmans J, Haesevoets A, Huebbers C, et al. (2012) Abstracts for the 5th European Conference on Head and Neck Oncology 18-21 April 2012 in Poznan, Poland. Eur Arch Otorhinolaryngol 269: 1311-1410 doi:10.1007/s00405-012-1960-4.
49. Moody CA, Laimins LA, (2010) Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 10: 550-560 doi:10.1038/nrc2886.
50. Arany I, Rady P, Tyring SK, (1993) Alterations in cytokine/antioncogene expression in skin lesions caused by "low-risk" types of human papillomaviruses. Viral Immunol 6: 255-265.
51. Armstrong DJ, Roman A, (1997) The Relative Ability of Human Papillomavirus Type 6 and Human Papillomavirus Type 16 E7 Proteins to Transactivate E2F-Responsive Elements Is Promoter- and Cell-Dependent. Virology 239: 238-246 doi:10.1006/viro.1997.8885.